Shots:

• Boehringer’s Ingelvac CSF MLV has obtained a New Veterinary Drug Registration Certificate from the Ministry of Agriculture and Rural Affairs of China
• The vaccine is jointly developed by Boehringer and Chinese research institutes and will be produced at BI’s Taizhou plant- Jiangsu province- and is expected to be commercialized in H1’21
• The vaccine is the BI’s first swine vaccine product- developed- manufactured and distributed in China. The plant also manufactures Ingelvac PRRS MLV (live vaccine for porcine reproductive and respiratory syndrome)

 ­ Ref: Boehringer Ingelheim | Image: Boehringer Ingelheim